Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb 28;32(3):142.
doi: 10.3390/curroncol32030142.

Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada

Isabelle Fleury  1 , David MacDonald  2 , Mona Shafey  3 , Anna Christofides  4 , Laurie H Sehn  5
Affiliations
Review

Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada

Isabelle Fleury et al. Curr Oncol. .

Abstract

CAR-T cell therapy has significantly improved outcomes for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but challenges such as limited resources, manufacturing timelines, and notable toxicities persist. Bispecific antibodies (BsAbs), including glofitamab and epcoritamab, have demonstrated promising efficacy and represent a new treatment option in patients who are unsuitable for or have relapsed following CAR-T therapy. Bispecific antibodies have a manageable safety profile and are generally more widely accessible than CAR-T cell therapy. Case discussions in this paper illustrate the potential real-world application of BsAbs, highlighting their role in treating patients who have relapsed after or are unable to undergo CAR-T cell therapy. Overall, glofitamab and epcoritamab represent valuable treatment options in the evolving landscape of R/R DLBCL.

Keywords: CAR-T therapy; bispecific antibodies; diffuse large B-cell lymphoma; epcoritamab; glofitamab; relapsed/refractory lymphoma.

PubMed Disclaimer

Conflict of interest statement

The authors acknowledge the medical writing support provided by Anna Christofides of IMPACT Medicom Inc. and funded by AbbVie Inc. IF. has received funding for advisory board and conference attendance from AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Incyte, Janssen, Roche, Pfizer, and Eli Lilly. L.H.S. has received consulting fees and honoraria from AbbVie, Amgen, AstraZeneca, BeiGene, BMS/Celgene, Genmab, Kite/Gilead, Incyte, Janssen, Merck, Seagen, and Roche/Genentech, as well as research funding from Roche/Genentech and Teva. M.S. has received honoraria for presentations or advisory board participation from AbbVie, AstraZeneca, BeiGene, BMS, Janssen, Kite/Gilead, Incyte, and Roche. D.M. has received honoraria for advisory board participation from AbbVie, AstraZeneca, BeiGene, Gilead, Pfizer, and Roche. AbbVie has provided funding for medical writing support in the development of this paper. The funders had no role in the writing of the manuscript.

References

    1. Thieblemont C., Karimi Y.H., Ghesquieres H., Cheah C.Y., Clausen M.R., Cunningham D., Jurczak W., Do Y.R., Gasiorowski R., Lewis D.J., et al. Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia. 2024;38:2653–2662. doi: 10.1038/s41375-024-02410-8. - DOI - PMC - PubMed
    1. Shafey M., Savage K., Skrabek P., Elsawy M., Bosch M., Kuruvilla J. Canadian Evidence-Based Guideline for the Treatment of Relapsed/Refractory: Diffuse Large B-Cell Lymphoma. Lymphoma Canada; Mississauga, ON, Canada: 2021.
    1. Dickinson M.J., Carlo-Stella C., Morschhauser F., Bachy E., Corradini P., Iacoboni G., Khan C., Wróbel T., Offner F., Trněný M., et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 2022;387:2220–2231. doi: 10.1056/NEJMoa2206913. - DOI - PubMed
    1. Davison K., Chen B.E., Kukreti V., Couban S., Benger A., Berinstein N.L., Kaizer L., Desjardins P., Mangel J., Zhu L., et al. Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: A subgroup analysis from the phase III CCTG LY.12 trial. Ann. Oncol. 2017;28:622–627. doi: 10.1093/annonc/mdw653. - DOI - PubMed
    1. Gisselbrecht C., Glass B., Mounier N., Singh Gill D., Linch D.C., Trneny M., Bosly A., Ketterer N., Shpilberg O., Hagberg H., et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J. Clin. Oncol. 2010;28:4184–4190. doi: 10.1200/JCO.2010.28.1618. - DOI - PMC - PubMed

Substances

Grants and funding

LinkOut - more resources